Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum Quiver Quantitative
Covered in this story
Analyst targets on Amgen
- BMO Capital Markets: $418 → $415 by Oct 2027 via GuruFocus
- Wells Fargo: $415 → $430 by Oct 2027 · Equal-Weight via GuruFocus
- Morgan Stanley: $415 → $359 by Oct 2027 · Equal Weight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 6 Oct 2026.
Summary aggregated from Quiver Quantitative's public RSS feed. The full reporting belongs to Quiver Quantitative — please read it on their site.